• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Foldrx Pharmaceuticals

edit

FoldRx Pharmaceuticals, Inc. engages in the discovery and development of disease modifying drug therapies for diseases of protein misfolding and amyloidosis. The companyТs pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy, and a discovery program in Parkinson’s disease and cystic fibrosis. FoldRx Pharmaceuticals, Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  Foldrx Pharmaceuticals was acquired by Pfizer. (9/1/10)
  Posted 9/6/10 at 10:47pm via foldrx.com
• 
  Foldrx Pharmaceuticals received $29M in Venture Round funding. (6/15/10)
  Posted 6/16/10 at 6:01am via fiercebiotech.com
• 
  Foldrx Pharmaceuticals added Richard Labaudinière as President and CEO.
  Posted 6/16/10 at 6:01am

Videos

Screenshots

edit

Sources

1. Pfizer To Acquire FoldRx Pharmaceuticals (foldrx.com) [edit]
2. FoldRx banks $29M for neurodegenerative drug application (fiercebiotech.com) [edit]